DrugPatentWatch Database Preview
ARANESP Drug Profile
» See Plans and Pricing
Summary for Tradename: ARANESP
Patents: | 94 |
Applicants: | 1 |
BLAs: | 1 |
Suppliers: see list | 1 |
Recent Clinical Trials: | See clinical trials for ARANESP |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for ARANESP |
Recent Clinical Trials for ARANESP
Identify potential brand extensions & biosimilar entrants
Sponsor | Phase |
---|---|
Zealand University Hospital | N/A |
Alberta Children's Hospital | Phase 2 |
Leiden University Medical Center | Phase 2/Phase 3 |
Recent Litigation for ARANESP
Identify key patents and potential future biosimilar entrants
District Court Litigation
Case Name | Date |
---|---|
Ameranth, Inc. v. Starbucks Corporation | 2013-05-06 |
Pharmacology for ARANESP
Ingredient-type | Erythropoietin |
Physiological Effect | Increased Erythroid Cell Production |
Company Disclosures: US Patents for ARANESP
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Amgen | ARANESP | darbepoetin alfa | VIAL; INTRAVENOUS | 103951 | 001 | 2001-09-17 | Start Trial | Kirin-Amgen, Inc. (Thousand Oaks, CA) | 2003-12-13 | RX | company | |
Amgen | ARANESP | darbepoetin alfa | VIAL; INTRAVENOUS | 103951 | 001 | 2001-09-17 | Start Trial | Amgen Inc. (Thousand Oaks, CA) | 2024-05-15 | RX | company | |
Amgen | ARANESP | darbepoetin alfa | VIAL; INTRAVENOUS | 103951 | 002 | 2001-09-17 | Start Trial | Kirin-Amgen, Inc. (Thousand Oaks, CA) | 2003-12-13 | RX | company | |
Amgen | ARANESP | darbepoetin alfa | VIAL; INTRAVENOUS | 103951 | 002 | 2001-09-17 | Start Trial | Amgen Inc. (Thousand Oaks, CA) | 2024-05-15 | RX | company | |
Amgen | ARANESP | darbepoetin alfa | VIAL; INTRAVENOUS | 103951 | 003 | 2001-09-17 | Start Trial | Kirin-Amgen, Inc. (Thousand Oaks, CA) | 2003-12-13 | RX | company | |
Amgen | ARANESP | darbepoetin alfa | VIAL; INTRAVENOUS | 103951 | 003 | 2001-09-17 | Start Trial | Amgen Inc. (Thousand Oaks, CA) | 2024-05-15 | RX | company | |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
Patent Text Search: US Patents for ARANESP
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Amgen | ARANESP | darbepoetin alfa | VIAL; INTRAVENOUS | 103951 | 001 | 2001-09-17 | Start Trial | SIO2 MEDICAL PRODUCTS, INC. (Auburn, AL) | 2033-03-11 | RX | search | |
Amgen | ARANESP | darbepoetin alfa | VIAL; INTRAVENOUS | 103951 | 001 | 2001-09-17 | Start Trial | AMGEN INC. (Thousand Oaks, CA) | 2039-02-26 | RX | search | |
Amgen | ARANESP | darbepoetin alfa | VIAL; INTRAVENOUS | 103951 | 001 | 2001-09-17 | Start Trial | 2036-04-01 | RX | search | ||
Amgen | ARANESP | darbepoetin alfa | VIAL; INTRAVENOUS | 103951 | 001 | 2001-09-17 | Start Trial | YALE UNIVERSITY (New Haven, CT) | 2039-02-26 | RX | search | |
Amgen | ARANESP | darbepoetin alfa | VIAL; INTRAVENOUS | 103951 | 001 | 2001-09-17 | Start Trial | GENOSCIENCE PHARMA (Marseilles, FR) | 2039-02-26 | RX | search | |
Amgen | ARANESP | darbepoetin alfa | VIAL; INTRAVENOUS | 103951 | 001 | 2001-09-17 | Start Trial | ChemoCentryx, Inc. (Mountain View, CA) | 2036-06-13 | RX | search | |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
International Patents for ARANESP
Country | Patent Number | Estimated Expiration |
---|---|---|
Hungary | 204889 | Start Trial |
Slovenia | 3494986 | Start Trial |
European Patent Office | 1907009 | Start Trial |
Japan | H0693000 | Start Trial |
Australia | 2007336873 | Start Trial |
Austria | 498620 | Start Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for ARANESP
Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|
PA2004015 | Lithuania | Start Trial | PRODUCT NAME: DARBEPOETINAS ALFA (ASN30 THR32 VAL87 ASN88 THR90 EPO); REGISTRATION NO/DATE: EU/1/01/185/001-030 20010608 |
43/2001 | Austria | Start Trial | PRODUCT NAME: DARBEPOETIN-ALFA; REGISTRATION NO/DATE: EU/1/01/185/001-030 20010608 |
132001900976055 | Italy | Start Trial | AUTHORISATION NUMBER(S) AND DATE(S): EU/1/01/185/1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19- 20-21-22-23-24-25-26-27-28-29-30, 20010608 |
SPC028/2001 | Ireland | Start Trial | SPC028/2001: 20031204, EXPIRES: 20160607 |
SZ 43/2001 | Austria | Start Trial | PRODUCT NAME: DARBEPOETIN-ALFA |
10199059 | Germany | Start Trial | PRODUCT NAME: DARBEPOETIN ALFA; REGISTRATION NO/DATE: EU/1/01/185/001-030 20010608 |
>Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |